RE:RE:RE:RE:RE:RE:RE:Reading the tea leavesHUGE is not paying $48million US simply as a means to get a NASDAQ listing. There is value in the medicle reseach TRPX has completed and the late stage trials they are in. There are many ways to get a NASDAQ listing that would not cost nearly $48million.
Without a deal TRPX is on life support temporaraly, but that is nothing new, you could see when they would run out of cash very easily in there Q1 financials. My estimates were off by about 1 months, probably becasue they have spent more on legal fees while working on deals with CURE and HUGE.
All Pharma companies go through this stage while they are developing new drugs/treatments. It takes a few years to go through the hoops before you can get approval to sell and make money. TRPX will issue more share or do another type of financing if they need to, the company will still be worth about what it was before this deal was anounced, $4-$5.00.
TRPX knows they are better off being aquired by a larger company with easier access to capital to help complete what they have started.